Drug Pricing
Our work in Drug Pricing
-
NBER Working Paper: Prescription Drug Advertising and Drug Utilization – The Role of Medicare Part D
This study examined how direct-to-consumer advertising influences drug utilization along the extensive and intensive margins by exploiting a large and plausibly exogenous shock to DTCA driven by the introduction of Medicare Part D in 2006.
Categorized in -
Drop Medicaid ‘Best Price’ Rule Drug Rules in Favor of Value-Based Strategies
The Medicaid Drug Rebate Program contributes significantly to a dysfunctional pricing process that undermines competition and inflates drug costs for those insured through employers, the individual market and government employee health benefit programs.
Categorized in -
For Vulnerable Populations, the Medicare Part D Doughnut Hole Disrupts Medication Adherence
Schaeffer Center researchers examined the impact of the Part D coverage gap on low-income and minority populations to determine if it changes individuals’ use of medications. Their findings show that the gap is particularly disruptive to minorities and low-income households.
Categorized in -
Understanding Patient Preferences and Willingness to Pay for Hemophilia Therapies
This study found that improvements in treatment effectiveness and dosing frequency, treatment side effects, and out-of-pocket costs per month were the greatest determinants of hemophilia treatment choice and willingness to pay.
Categorized in -
Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern
This study shows that treating 5 percent of all hepatitis C patients with the latest drugs would be more effective at reducing infections and health care costs than the current approach.
Categorized in -
Promise of Precision Medicine
In this comment on a previously published article, the authors say that the article highlighted the promise of precision medicine to improve health benefits and cost savings, citing “highly cost-effective” genetic testing to screen for familial hypercholesterolemia as an example, but cited only one favorable cost-effectiveness estimate specific to the UK and did not mention relevant alternatives.
Categorized in -
Treating 5 percent of hepatitis C patients with new drugs would reduce cost and infections, study shows
The health care system would save more lives and money if patients were treated with the latest drugs earlier, researchers at USC and other institutions find.
Categorized in -
A New Line of Specialty Drugs: PCSK9 Inhibitors (Part 2)
The major group likely to benefit are people with Familial Hypercholesterolemia (FH)- an inherited disorder effecting around one in 500 Americans.
Categorized in -
What’s a Fair Price? The Debate Over Value & Cost of Specialty Drugs (Part 1)
How do we make these treatments affordable and accessible to those who need them most while ensuring quality care and encouraging new innovation?
Categorized in -
Moving Beyond Price-Per-Dose In The Pharmaceutical Industry
Editor’s note: The blog was first published on Health Affairs on September 30, 2015. The United States has experienced extraordinary gains in treating cardiovascular disease over the last few decades. Statins, introduced in the 1980’s, are an important part of the story. Hundreds of thousands of deaths, heart attacks, and strokes have been prevented due to lower […]
Categorized in